Pharma Medtech News Today

In a move towards advancing research and innovation in the pharmaceutical and medical technology (Pharma-MedTech) sector, the Ministry of Finance announced

The race for Johnson & Johnson's (NYSE: JNJ) top executive position has intensified following the unexpected exit of Ashley McEvoy, the former head of the company's medical device unit, potentially altering the anticipated succession plans within the healthcare giant

“Today is a historic day, an inflection point in the journey of "Atmanirbharta" in the pharma & medical devices sector. We need to transform Indian Pharma & MedTech sectors from a cost-based to a value-based & innovation-based industry.”

REFINITIV STREETEVENTS EDITED TRANSCRIPT JNJ.N - Johnson & Johnson at Morgan Stanley Global Healthcare Conference ...

Investegate announcements from JPMorgan Global, Final Results to 30th June 2022

In 2000, Asia’s share of global GDP was around 28%.[1] In 2019, Asia generated nearly 40% of the world’s GDP and is now home to nearly 60% of the world’s population. According to McKinsey & Co, “Asia is on track to top 50% of global GDP by 2040 and drive 40% of the world’s consumption, representing a real shift in the world’s centre of gravity.”[2]

The Irish Times Business Person of the Month: Matt Cooper Inflazome sells to Swiss pharma giant Roche for an initial €380 million Tue, Apr 13, 2021, 02:06   The spark behind Inflazome came when Australian chemist Matt Cooper met Irish immunologist Luke O’Neill at a medical conference. The two men brainstormed the role of inflammasomes - part of the body’s immune system - in a host of serious chronic diseases when they spiral out of control. Eight years later - and four years after the ...

Open Orphan plans for possible spin-out of non-core assets Company says HVO-001 could be included as part of potential demerger Tue, Apr 13, 2021, 07:45 Updated: Tue, Apr 13, 2021, 16:57   Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets. The company said it believed the assets in question were best developed separately from the core services businesses to maximise sha...

CDC makes first public admission that there are efficacy problems with domestic jabs

Blueprint requires members of billionaire pharmacy family to relinquish control of company